JP6629210B2 - エンベロープウイルスの産生方法 - Google Patents
エンベロープウイルスの産生方法 Download PDFInfo
- Publication number
- JP6629210B2 JP6629210B2 JP2016542356A JP2016542356A JP6629210B2 JP 6629210 B2 JP6629210 B2 JP 6629210B2 JP 2016542356 A JP2016542356 A JP 2016542356A JP 2016542356 A JP2016542356 A JP 2016542356A JP 6629210 B2 JP6629210 B2 JP 6629210B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- lentivirus
- medium
- cells
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000700605 Viruses Species 0.000 title claims description 71
- 238000004519 manufacturing process Methods 0.000 title description 31
- 238000000034 method Methods 0.000 claims description 40
- 230000002378 acidificating effect Effects 0.000 claims description 38
- 241000713666 Lentivirus Species 0.000 claims description 34
- 239000013612 plasmid Substances 0.000 claims description 34
- 230000008569 process Effects 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 29
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 24
- 108700019146 Transgenes Proteins 0.000 claims description 13
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 12
- 101710091045 Envelope protein Proteins 0.000 claims description 9
- 101710188315 Protein X Proteins 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 7
- 241000714230 Avian leukemia virus Species 0.000 claims description 6
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 5
- 241001485018 Baboon endogenous virus Species 0.000 claims description 4
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 4
- 241000714474 Rous sarcoma virus Species 0.000 claims description 4
- 241000710961 Semliki Forest virus Species 0.000 claims description 4
- 101150047047 gag-pol gene Proteins 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 108700004030 rev Genes Proteins 0.000 claims description 4
- 101150098213 rev gene Proteins 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 241000712892 Arenaviridae Species 0.000 claims description 2
- 241000701412 Baculoviridae Species 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims description 2
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 2
- 241000725171 Mokola lyssavirus Species 0.000 claims description 2
- 241000711408 Murine respirovirus Species 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 241000712907 Retroviridae Species 0.000 claims description 2
- 241000711931 Rhabdoviridae Species 0.000 claims description 2
- 241000710942 Ross River virus Species 0.000 claims description 2
- 241000710960 Sindbis virus Species 0.000 claims description 2
- 241000713675 Spumavirus Species 0.000 claims description 2
- 241000710924 Togaviridae Species 0.000 claims description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 2
- 241000711970 Vesiculovirus Species 0.000 claims description 2
- 241000713325 Visna/maedi virus Species 0.000 claims description 2
- 241000710951 Western equine encephalitis virus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 6
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 claims 1
- 241000710781 Flaviviridae Species 0.000 claims 1
- 241000711504 Paramyxoviridae Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 49
- 239000002609 medium Substances 0.000 description 46
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 29
- 239000002245 particle Substances 0.000 description 25
- 208000015181 infectious disease Diseases 0.000 description 21
- 230000002458 infectious effect Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000001177 retroviral effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 101710205625 Capsid protein p24 Proteins 0.000 description 7
- 101710177166 Phosphoprotein Proteins 0.000 description 7
- 101710149279 Small delta antigen Proteins 0.000 description 7
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241001663880 Gammaretrovirus Species 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 241000713730 Equine infectious anemia virus Species 0.000 description 3
- 241000713800 Feline immunodeficiency virus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 201000005505 Measles Diseases 0.000 description 3
- 241000713311 Simian immunodeficiency virus Species 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 241001203868 Autographa californica Species 0.000 description 2
- 241001231757 Betaretrovirus Species 0.000 description 2
- 241000537219 Deltabaculovirus Species 0.000 description 2
- 241001663879 Deltaretrovirus Species 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 101000852024 Gibbon ape leukemia virus Envelope glycoprotein Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000010094 Visna Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241001664176 Alpharetrovirus Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001663878 Epsilonretrovirus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000035314 Henipavirus Species 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 241000713673 Human foamy virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001504654 Mustela nivalis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241000785681 Sander vitreus Species 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- -1 cell density Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1358909 | 2013-09-16 | ||
| FR1358909A FR3010720B1 (fr) | 2013-09-16 | 2013-09-16 | Procede de production de virus enveloppes |
| PCT/FR2014/052279 WO2015036713A1 (fr) | 2013-09-16 | 2014-09-12 | Procede de production de virus enveloppes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530890A JP2016530890A (ja) | 2016-10-06 |
| JP2016530890A5 JP2016530890A5 (enExample) | 2017-10-19 |
| JP6629210B2 true JP6629210B2 (ja) | 2020-01-15 |
Family
ID=50424334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542356A Ceased JP6629210B2 (ja) | 2013-09-16 | 2014-09-12 | エンベロープウイルスの産生方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10125352B2 (enExample) |
| EP (1) | EP3047025B1 (enExample) |
| JP (1) | JP6629210B2 (enExample) |
| CN (1) | CN105722984B (enExample) |
| CA (1) | CA2923554C (enExample) |
| DK (1) | DK3047025T3 (enExample) |
| ES (1) | ES2732154T3 (enExample) |
| FR (1) | FR3010720B1 (enExample) |
| RU (1) | RU2016114541A (enExample) |
| SG (1) | SG11201602017YA (enExample) |
| WO (1) | WO2015036713A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
| KR20180108567A (ko) | 2015-10-22 | 2018-10-04 | 주노 테라퓨틱스 게엠베하 | 형질도입을 위한 방법, 키트, 제제 및 장치 |
| US12037599B2 (en) | 2019-08-23 | 2024-07-16 | Lonza Walkersville, Inc. | Methods and constructs for production of lentiviral vector |
| TW202246517A (zh) | 2021-01-28 | 2022-12-01 | 美商異基因治療有限公司 | 用於轉導免疫細胞之方法 |
| US20250059560A1 (en) * | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5110696B2 (ja) | 2004-11-05 | 2012-12-26 | ウェルスタット バイオロジクス コーポレイション | 安定かつ濾過可能なエンベロープで覆われたウイルス処方物 |
| US7875446B2 (en) | 2006-04-20 | 2011-01-25 | Wyeth Llc | Purification processes for isolating purified vesicular stomatitis virus from cell culture |
| DK3192874T3 (da) | 2008-06-18 | 2019-12-16 | Oxford Biomedica Ltd | Virusoprensning |
| US10596264B2 (en) * | 2011-06-30 | 2020-03-24 | Genethon | Peptides with viral infection enhancing properties and their use |
| ES2663815T3 (es) | 2011-11-24 | 2018-04-17 | Genethon | Sistema de producción de un vector lentiviral escalable compatible con aplicaciones farmacéuticas industriales |
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
-
2013
- 2013-09-16 FR FR1358909A patent/FR3010720B1/fr not_active Expired - Fee Related
-
2014
- 2014-09-12 JP JP2016542356A patent/JP6629210B2/ja not_active Ceased
- 2014-09-12 ES ES14796166T patent/ES2732154T3/es active Active
- 2014-09-12 EP EP14796166.8A patent/EP3047025B1/fr not_active Revoked
- 2014-09-12 DK DK14796166.8T patent/DK3047025T3/da active
- 2014-09-12 CA CA2923554A patent/CA2923554C/fr not_active Expired - Fee Related
- 2014-09-12 RU RU2016114541A patent/RU2016114541A/ru not_active Application Discontinuation
- 2014-09-12 WO PCT/FR2014/052279 patent/WO2015036713A1/fr not_active Ceased
- 2014-09-12 CN CN201480050980.4A patent/CN105722984B/zh not_active Expired - Fee Related
- 2014-09-12 US US15/022,049 patent/US10125352B2/en not_active Expired - Fee Related
- 2014-09-12 SG SG11201602017YA patent/SG11201602017YA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2732154T3 (es) | 2019-11-20 |
| US10125352B2 (en) | 2018-11-13 |
| CA2923554C (fr) | 2019-10-29 |
| CN105722984B (zh) | 2021-08-13 |
| EP3047025A1 (fr) | 2016-07-27 |
| US20160230147A1 (en) | 2016-08-11 |
| CA2923554A1 (fr) | 2015-03-19 |
| WO2015036713A1 (fr) | 2015-03-19 |
| JP2016530890A (ja) | 2016-10-06 |
| CN105722984A (zh) | 2016-06-29 |
| RU2016114541A (ru) | 2017-10-23 |
| EP3047025B1 (fr) | 2019-04-03 |
| SG11201602017YA (en) | 2016-04-28 |
| FR3010720A1 (fr) | 2015-03-20 |
| DK3047025T3 (da) | 2019-06-24 |
| FR3010720B1 (fr) | 2017-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2413995C (en) | Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity | |
| Kobayashi et al. | Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus | |
| JP6629210B2 (ja) | エンベロープウイルスの産生方法 | |
| Patel et al. | High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors | |
| CA2754603A1 (en) | Non-integrating retroviral vector vaccines | |
| Radoshitzky et al. | Ebolavirus Δ-peptide immunoadhesins inhibit Marburgvirus and Ebolavirus cell entry | |
| Wang et al. | Pseudotyped viruses | |
| Liu et al. | HIV-1-based lentiviral vectors | |
| JP2024028802A (ja) | レンチウイルスパッケージングシステム、それにより製造されたレンチウイルス、及び、該レンチウイルスで形質導入された細胞、並びに、それを使用して宿主細胞のレンチウイルスの収率を向上させる方法 | |
| WO2024044655A1 (en) | Delivery of heterologous proteins | |
| CN113166782A (zh) | 增强慢病毒载体产生的方法 | |
| US9840720B2 (en) | Materials and methods relating to packaging cell lines | |
| Olgun et al. | High-titer production of HIV-based lentiviral vectors in roller bottles for gene and cell therapy | |
| Schüle et al. | Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj | |
| JP2013208107A (ja) | レトロウイルスベクターの製造方法 | |
| US7981656B2 (en) | Pseudotyped retrovirus with modified ebola glycoprotein | |
| Gilbert et al. | Protein production using lentiviral vectors | |
| EP2366776A1 (en) | A method for measuring viral infectivity | |
| WO2024194651A1 (en) | Expression construct | |
| Bauer et al. | Gene therapy vectors | |
| TW202540399A (zh) | 用於有效包裹病毒顆粒之經修改的細胞株 | |
| KR20250167656A (ko) | 발현 컨스트럭트 | |
| Costa | New cell lines for the manufacture of lentivirus | |
| HK1056576B (en) | Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity | |
| HK1055133A (en) | Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170906 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170906 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180627 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180919 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190521 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190807 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191018 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191204 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6629210 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| RVOP | Cancellation by post-grant opposition |